RxDoctor Payments Data

Elizabeth Hunter, MD

Family Medicine · Ashland, KYNPI 1831572262

Payments from drug & device makers

$614in general payments, 2019–2025

Across 34 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • CSL Behring$101
  • Dexcom, Inc.$54
  • GSK$40
  • Biohaven Pharmaceuticals, Inc.$38
  • Daiichi Sankyo Inc.$37
  • plus $112 from 5 others

What the payments were for

  • Food & beverage$614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$614 in reported general payments places this provider in the 45th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$45,937
Medicare patients
151
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$160,754
MounjaroTirzepatide50$60,142
EliquisApixaban58$57,892
JanuviaSitagliptin Phosphate38$50,730
LinzessLinaclotide52$39,384
JardianceEmpagliflozin40$33,603
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$30,764
FarxigaDapagliflozin Propanediol30$19,172
XareltoRivaroxaban11$17,951
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$16,289
Tresiba Flextouch U-200Insulin Degludec13$14,905
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$11,447
Breo ElliptaFluticasone/Vilanterol21$9,021
VascepaIcosapent Ethyl17$8,760
Spiriva HandihalerTiotropium Bromide15$8,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$160,754138 claims
Lilly USA, LLCMounjaro$20$60,14250 claims
PfizerEliquis$27$57,89258 claims
GSKTrelegy Ellipta, Breo Ellipta$40$39,78552 claims
AbbVieLinzess$234$39,38452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →